[go: up one dir, main page]

AU2001259758A1 - Interleukin-1 inhibitors in the treatment of diseases - Google Patents

Interleukin-1 inhibitors in the treatment of diseases

Info

Publication number
AU2001259758A1
AU2001259758A1 AU2001259758A AU5975801A AU2001259758A1 AU 2001259758 A1 AU2001259758 A1 AU 2001259758A1 AU 2001259758 A AU2001259758 A AU 2001259758A AU 5975801 A AU5975801 A AU 5975801A AU 2001259758 A1 AU2001259758 A1 AU 2001259758A1
Authority
AU
Australia
Prior art keywords
interleukin
inhibitors
diseases
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259758A
Inventor
Timothy Connor
F. Ann Hayes
Larry F. O'neal
John E. Sims
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU2001259758A1 publication Critical patent/AU2001259758A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
AU2001259758A 2000-05-12 2001-05-11 Interleukin-1 inhibitors in the treatment of diseases Abandoned AU2001259758A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20388100P 2000-05-12 2000-05-12
US60/203,881 2000-05-12
US22242200P 2000-08-01 2000-08-01
US60/222,422 2000-08-01
PCT/US2001/015423 WO2001087328A2 (en) 2000-05-12 2001-05-11 Interleukin-1 inhibitors in the treatment of diseases

Publications (1)

Publication Number Publication Date
AU2001259758A1 true AU2001259758A1 (en) 2001-11-26

Family

ID=26898999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259758A Abandoned AU2001259758A1 (en) 2000-05-12 2001-05-11 Interleukin-1 inhibitors in the treatment of diseases

Country Status (4)

Country Link
US (3) US20010053764A1 (en)
EP (4) EP1712239A3 (en)
AU (1) AU2001259758A1 (en)
WO (1) WO2001087328A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7811990B2 (en) * 1998-09-25 2010-10-12 Sciaticon Ab Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US7906481B2 (en) 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
SE9803710L (en) 1998-09-25 2000-03-26 A & Science Invest Ab Use of certain substances for the treatment of nerve root damage
WO2000029581A1 (en) 1998-11-13 2000-05-25 Immunex Corporation Human tslp dna and polypeptides
ES2422879T3 (en) 2001-07-23 2013-09-16 Immunex Corporation Modified human thymic stromal lymphopoietin
MXPA04001187A (en) * 2001-08-07 2004-07-08 Immunex Corp Interleukin-1 receptors in the treatment of diseases.
EP1471931A4 (en) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst COPPER-DEPENDENT, NON-TRADITIONAL PROINFLAMMATORY CYTOKINE EXPORT AND METHODS, COMPOSITIONS AND KITS THAT CONCERN THESE
WO2003057162A2 (en) * 2002-01-04 2003-07-17 Combinatorx, Incorporated Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
CN1761487A (en) * 2003-03-20 2006-04-19 法玛西雅公司 Dispersible formulation of an anti-inflammatory agent
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US20050171015A1 (en) * 2003-10-31 2005-08-04 Crabtree Gerald R. Methods and agents for enhancing bone formation or preventing bone loss
US7615212B2 (en) * 2004-02-26 2009-11-10 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
US7563804B1 (en) * 2004-04-19 2009-07-21 Hovanes John Ter-Zakarian FMF treatment
WO2005117945A1 (en) * 2004-06-04 2005-12-15 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (en) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． Synthetic advanced glycosylated protease resistant polypeptide variants, oral formulations and methods using the same
AU2005277236A1 (en) * 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
EP1807109A2 (en) * 2004-10-05 2007-07-18 Ochsner Clinic Foundation Enhancement of b cell proliferation by il-15
RU2007117716A (en) * 2004-10-12 2008-11-20 Ампротеин Корпорейшн (Us) CHIMERIC PROTEIN
US20060160737A1 (en) * 2005-01-14 2006-07-20 Allen Radin Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
WO2006124961A2 (en) * 2005-05-16 2006-11-23 Children's Medical Center Corporation Method of treating lymphangioleiomyomatosis (lam)
SI2163562T1 (en) * 2005-06-21 2014-01-31 Xoma (Us) Llc IL-1beta binding antibodies and fragments thereof
WO2007047969A2 (en) * 2005-10-21 2007-04-26 Amgen Inc. Methods of decreasing vascular calcification using il-1 inhibitors
DK2848258T3 (en) * 2005-10-26 2018-03-19 Novartis Ag Treatment of familial Mediterranean fever with anti-IL-1beta antibodies
JP5645409B2 (en) * 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー Method for treating IL-1β related diseases
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2008257520B2 (en) * 2007-05-29 2012-04-05 Novartis Ag New indications for anti- IL-I-beta therapy
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2187901B1 (en) * 2007-09-11 2012-08-08 Mondobiotech Laboratories AG Neuropeptide El optionally combined with ACTH (7-38) for use in anti-angiogenic therapy
JP2010539038A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of Tyr-W-MIF-1 and urocortin 2 as therapeutic agents
AU2008303954A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of Pseudomonas aeruginosa infection
PL2391650T3 (en) * 2007-12-20 2015-03-31 Xoma Us Llc Methods for the treatment of gout
US20090191287A1 (en) * 2008-01-29 2009-07-30 Johnson W Dudley Mitigation of Inflammation-Related Injuries
US8753690B2 (en) * 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
PT2293816E (en) * 2008-06-06 2013-02-13 Xoma Technology Ltd Methods for the treatment of rheumatoid arthritis
US20100069343A1 (en) * 2008-07-18 2010-03-18 Andrea Vambutus Methods of predicting steroid responsiveness with Il-1RII
WO2010028275A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
AU2010292486B2 (en) 2009-08-27 2014-08-07 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
CN102497885A (en) * 2009-09-10 2012-06-13 赛托斯生物技术公司 Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
CN101690801B (en) * 2009-10-26 2012-08-01 上海交通大学 Application of interleukin-1 receptor antagonist and medicinal composition thereof
AU2011239402A1 (en) * 2010-04-16 2012-10-25 Mcmaster University Compositions and methods for treating COPD exacerbation
JP5904645B2 (en) 2010-05-07 2016-04-13 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー Methods for the treatment of IL-1β related pathologies
HRP20230776T1 (en) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Chimeric il-1 receptor type i antagonists
KR20140003398A (en) 2010-09-03 2014-01-09 바이오멧 바이오로직스, 엘엘씨 Methods and compositions for delivering interleukin-1 receptor antagonist
MX2015012404A (en) 2013-03-13 2016-02-03 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery.
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
GB201412410D0 (en) * 2014-07-11 2014-08-27 Isis Innovation Treatment
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
JP2022535595A (en) * 2019-06-07 2022-08-09 セレクティミューン ファーマ アクチエボラグ Treatment and diagnosis of chronic inflammatory conditions in the lower urinary tract

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5096906A (en) 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5196430A (en) 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5296592A (en) * 1987-11-25 1994-03-22 Immunex Corporation Process for purifying interleukin-1 receptors
USRE35450E (en) 1987-11-25 1997-02-11 Immunex Corporation Soluble human interleukin-1 receptors, compositions and method of use
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
DE3817955A1 (en) 1988-05-27 1989-11-30 Hoechst Ag MEDICINAL PRODUCT CONTAINING TNF INHIBITOR
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US5064837A (en) * 1989-11-13 1991-11-12 Schering Corporation 3-substituted-1-aryl-2(h)-quinolones and their pharmaceutical compositions
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
AU7775991A (en) 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
WO1991017184A1 (en) 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
US5872095A (en) * 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
ES2251009T3 (en) 1990-06-28 2006-04-16 Sanofi-Aventis Deutschland Gmbh FUSION PROTEINS WITH PARTS OF IMMUNOGLOBULINS, THEIR PREPARATION AND USE.
ATE142494T1 (en) * 1990-11-30 1996-09-15 Teijin Ltd 2-ARYLTHIAZOLE DERIVATIVE AND MEDICINAL PRODUCT CONTAINING THIS
WO1992012724A1 (en) * 1991-01-17 1992-08-06 The Upjohn Company Method of preventing and treating insulin dependent diabetes mellitus
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DK0600880T3 (en) 1991-08-30 2004-04-13 Vertex Pharma Interleukin 1 beta protease and interleukin 1 beta protease inhibitors
WO1993007863A1 (en) * 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
WO1993014777A1 (en) 1992-01-31 1993-08-05 Merck & Co., Inc. PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
JP3386125B2 (en) 1992-02-21 2003-03-17 メルク エンド カンパニー インコーポレーテッド Peptidyl derivatives as interleukin-1β converting enzyme inhibitors
US5547979A (en) 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
EP0639079B1 (en) * 1992-04-30 2000-01-12 Amgen Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
DK0628550T3 (en) 1993-06-08 1998-09-28 Vertex Pharma Pyridazine as interleukin-1 beta-converted enzyme inhibitors
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
DE19581347T1 (en) 1994-01-20 1996-12-05 British Biotech Pharm Metalloproteinase inhibitors
CA2186511C (en) 1994-03-31 2009-02-10 Roland E. Dolle Pyrimidinyl derivatives as interleukin inhibitors
US5519000A (en) 1994-04-01 1996-05-21 Centecor, Inc. Tumor necrosis factor inhibitors
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
CA2192821A1 (en) * 1994-06-24 1996-01-04 Wayne R. Gombotz Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
IT1269989B (en) 1994-09-21 1997-04-16 Dompe Spa IL-1 RECEPTOR ANTAGONISTS WITH INCREASED INHIBITORY ACTIVITY
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (en) 1995-04-20 2001-04-30 Pfizer ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS
US5641751A (en) 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
US5753628A (en) 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
CA2539273C (en) * 1996-02-09 2014-02-04 Amgen Inc. A fusion protein comprising an interleukin-1 receptor antagonist and uses thereof
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
CA2248551A1 (en) * 1996-03-15 1997-09-18 The General Hospital Corporation Programmed cell death and interleukin-1.beta.
US5874592A (en) * 1996-04-03 1999-02-23 Kyowa Hakko Kogyo Co., Ltd. Physiologically active substance EI-2128-1
GB9607120D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
EP0912519A1 (en) 1996-05-20 1999-05-06 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
DE69700616T2 (en) * 1996-07-02 2000-03-16 Nisshin Flour Milling Co., Ltd. Imide derivatives
US6054559A (en) * 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US5883131A (en) 1997-07-09 1999-03-16 Pfizer Inc. Cyclic sulfone derivatives
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6306978B1 (en) * 1999-02-05 2001-10-23 General Electric Company Capping of polyphenylene ether resin
US6086095A (en) 1999-07-30 2000-07-11 Milliken & Company Airbag cushion exhibiting low seam and fabric usage and simultaneously high available inflation volume
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes

Also Published As

Publication number Publication date
US20010053764A1 (en) 2001-12-20
EP2329842A3 (en) 2011-07-27
EP2241328A1 (en) 2010-10-20
US20040023869A1 (en) 2004-02-05
EP2329842A2 (en) 2011-06-08
WO2001087328A2 (en) 2001-11-22
US20090022733A1 (en) 2009-01-22
EP1282435A2 (en) 2003-02-12
EP1712239A2 (en) 2006-10-18
EP1712239A3 (en) 2007-08-22
WO2001087328A3 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
EP1450837A4 (en) Interleukin-1 receptors in the treatment of diseases
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU2002326600A1 (en) Side-exit catheter and method for its use
AU2002358270A1 (en) Zero-order sustained released dosage forms and method of making the same
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AUPR074500A0 (en) Treatment of t cell disorders
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001292019A1 (en) Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AU2001236713A1 (en) Methods for treatment of lysosomal storage diseases
AU2001260834A1 (en) The treatment of herpes
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases